Trial Profile
Weekly paclitaxel in combination with bevacizumab in patient with HER2 nagative breast cancer who were previously treated with taxane - PhaseII
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 26 Sep 2018
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Paclitaxel (Primary)
- Indications Breast cancer
- Focus Therapeutic Use
- Acronyms CARP
- 18 Sep 2018 Status changed from recruiting to completed.
- 16 Jan 2013 New trial record